Distinct Sets of Genetic Alterations in Melanoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Exposure to ultraviolet light is a major causative factor in melanoma, although the relationship between risk and exposure is complex. We hypothesized that the clinical heterogeneity is explained by genetically distinct types of melanoma with different susceptibility to ultraviolet light. METHODS: We compared genome-wide alterations in the number of copies of DNA and mutational status of BRAF and N-RAS in 126 melanomas from four groups in which the degree of exposure to ultraviolet light differs: 30 melanomas from skin with chronic sun-induced damage and 40 melanomas from skin without such damage; 36 melanomas from palms, soles, and subungual (acral) sites; and 20 mucosal melanomas. RESULTS: We found significant differences in the frequencies of regional changes in the number of copies of DNA and mutation frequencies in BRAF among the four groups of melanomas. Samples could be correctly classified into the four groups with 70 percent accuracy on the basis of the changes in the number of copies of genomic DNA. In two-way comparisons, melanomas arising on skin with signs of chronic sun-induced damage and skin without such signs could be correctly classified with 84 percent accuracy. Acral melanoma could be distinguished from mucosal melanoma with 89 percent accuracy. Eighty-one percent of melanomas on skin without chronic sun-induced damage had mutations in BRAF or N-RAS; the majority of melanomas in the other groups had mutations in neither gene. Melanomas with wild-type BRAF or N-RAS frequently had increases in the number of copies of the genes for cyclin-dependent kinase 4 (CDK4) and cyclin D1 (CCND1), downstream components of the RAS-BRAF pathway. CONCLUSIONS: The genetic alterations identified in melanomas at different sites and with different levels of sun exposure indicate that there are distinct genetic pathways in the development of melanoma and implicate CDK4 and CCND1 as independent oncogenes in melanomas without mutations in BRAF or N-RAS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these mutations are not UV-signature mutations20, they are more common in sun-exposed skin20–23.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language for Data Analysis and Graphics
Ihaka, R., & Gentleman, R. (1996) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1996.10474713 · Cited by 11,220
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data
Dudoit, S., Fridlyand, J., & Speed, T. P. (2002) · Journal of the American Statistical Association · doi:10.1198/016214502753479248 · Cited by 2,672
Self-citationPinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo, W.-L., Chen, C., Zhai, Y., et al. (1998) · Nature Genetics · doi:10.1038/2524 · Cited by 2,240
Self-citationThe histogenesis and biologic behavior of primary human malignant melanomas of the skin.
Clark, W. H., From, L., Bernardino, E. A., & Mihm, M. C. (1969) · PubMed · Cited by 2,112
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
LOWESS: A Program for Smoothing Scatterplots by Robust Locally Weighted Regression
Cleveland, W. S. (1981) · The American Statistician · doi:10.2307/2683591 · Cited by 1,150
Cited by
Items 601–700 of 1,006
Translational pathology, genomics and the development of systemic therapies for acral melanoma
Chen, Y. A., Teer, J. K., Eroglu, Z., Wu, J.-Y., Koomen, J. M., Karreth, F. A., Messina, J. L., & Smalley, K. S. M. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.017 · Cited by 65
Poorman, K. A., Borst, L. B., Moroff, S. D., Roy, S., Labelle, P., Motsinger‐Reif, A. A., & Breen, M. (2014) · Chromosome Research · doi:10.1007/s10577-014-9444-6 · Cited by 65
North, J. P., Vetto, J. T., Murali, R., White, K. P., White, C. R., & Bastian, B. C. (2011) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318222a634 · Cited by 65
Self-citationAssessment of BRAF and KIT mutations in Japanese melanoma patients
Ashida, A., Uhara, H., Kiniwa, Y., Oguchi, M., Murata, H., Goto, Y., Uchiyama, A., Ogawa, E., Hayashi, K., Koga, H., et al. (2012) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2012.03.005 · Cited by 65
Mathieu, V., Pirker, C., Schmidt, W. M., Spiegl‐Kreinecker, S., Lötsch, D., Heffeter, P., Hegedűs, B., Grusch, M., Kiss, R., & Berger, W. (2012) · Oncotarget · doi:10.18632/oncotarget.473 · Cited by 65
New Strategies in Melanoma: Molecular Testing in Advanced Disease
Woodman, S. E., Lazar, A. J., Aldape, K., & Davies, M. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2317 · Cited by 66
Ahmed, K. A., Freilich, J. M., Sloot, S., Figura, N. B., Gibney, G. T., Weber, J. S., Sarangkasiri, S., Chinnaiyan, P., Forsyth, P. A., Etame, A. B., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1685-x · Cited by 65
(Neo)adjuvant systemic therapy for melanoma
van Zeijl, M. C. T., van den Eertwegh, A. J. M., Haanen, J. B. A. G., & Wouters, M. W. J. M. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.07.001 · Cited by 65
Mutation status among patients with sinonasal mucosal melanoma and its impact on survival
Amit, M., Tam, S. H., Abdelmeguid, A. S., Roberts, D. B., Takahashi, Y., Raza, S. M., Su, S. Y., Kupferman, M. E., DeMonte, F., & Hanna, E. Y. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.125 · Cited by 65
Kenawy, N., Kalirai, H., Sacco, J. J., Lake, S. L., Heegaard, S., Larsen, A., Finger, P. T., Milman, T., Chin, K. J., Mosci, C., et al. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12767 · Cited by 65
Topical therapies for skin cancer and actinic keratosis
Haque, T., Rahman, K. M., Thurston, D. E., Hadgraft, J., & Lane, M. E. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.06.013 · Cited by 65
Noncutaneous Melanoma Have Distinct Features from Each Other and Cutaneous Melanoma
Taş, F., Keskın, S., Karadeniz, A. N., Dağoğlu, N., Şen, F., Kılıç, L., & Yıldız, İ. (2011) · Oncology · doi:10.1159/000334863 · Cited by 65
PAX3 expression in primary melanomas and nevi
Plummer, R. S., Shea, C. R., Nelson, M., Powell, S., Freeman, D. M., Dan, C. P., & Lang, D. (2008) · Modern Pathology · doi:10.1038/modpathol.3801019 · Cited by 65
CXCL-10: a new candidate for melanoma therapy?
Bagheri, H., Pourhanifeh, M. H., Derakhshan, M., Mahjoubin‐Tehran, M., Ghasemi, F., Mousavi, S., Rafiei, R., Abbaszadeh‐Goudarzi, K., Mirzaei, H. R., & Mirzaei, H. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00501-z · Cited by 65
The functional relevance of somatic synonymous mutations in melanoma and other cancers
Gotea, V., Gartner, J. J., Qutob, N., Elnitski, L. L., & Samuels, Y. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12413 · Cited by 64
Inhibition of autophagy with chloroquine is effective in melanoma
Egger, M. E., Huang, J. S., Yin, W., McMasters, K. M., & McNally, L. R. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.04.055 · Cited by 66
Solit, D. B., Santos, E. B., Pratilas, C. A., Lobo, J. M., Moroz, M. A., Cai, S., Blasberg, R., Sebolt, J. S., Larson, S. M., & Rosen, N. X. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2976 · Cited by 64
Morandi, L., de Biase, D., Visani, M., Cesari, V., Maglio, G. D., Pizzolitto, S., Pession, A., & Tallini, G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036084 · Cited by 64
The role of CCND1 alterations during the progression of cutaneous malignant melanoma
Vízkeleti, L., Ecsedi, S., Rákosy, Z., Teráz-Orosz, A., Lázár, V., Emri, G., Koroknai, V., Kiss, T., Ádány, R., & Balázs, M. (2012) · Tumor Biology · doi:10.1007/s13277-012-0480-6 · Cited by 64
Wang, L., Zehir, A., Sadowska, J., Zhou, N., Rosenblum, M. K., BUSAM, K. J., Agaram, N. P., Travis, W. D., Arcila, M. E., Doğan, S., et al. (2015) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22254 · Cited by 64
Self-citationTargeting mutant NRAS signaling pathways in melanoma
Vu, H. L., & Aplin, A. E. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.03.007 · Cited by 65
Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA
Gremel, G., Lee, R. J., Girotti, M. R., Mandal, A. K., Valpione, S., Garner, G., Ayub, M., Wood, S., Rothwell, D. G., Fusi, A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw278 · Cited by 59
Simbulan-Rosenthal, C. M., Dakshanamurthy, S., Gaur, A., Chen, Y.-S., Fang, H.-B., Abdussamad, M., Zhou, H., Zapas, J., Calvert, V., Petricoin, E. F., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14990 · Cited by 63
Ultraviolet light and melanoma
Craig, S., Earnshaw, C. H., & Virós, A. (2018) · The Journal of Pathology · doi:10.1002/path.5039 · Cited by 65
Fujii, S., Ishibashi, T., Kokura, M., Fujimoto, T., Matsumoto, S., Shidara, S., Kurppa, K. J., Pape, J., Catón, J., Morgan, P. R., et al. (2021) · The Journal of Pathology · doi:10.1002/path.5814 · Cited by 64
Ricotti, C., Bouzari, N., Agadi, A., & Cockerell, C. J. (2009) · Medical Clinics of North America · doi:10.1016/j.mcna.2009.08.011 · Cited by 63
Update on the Targeted Therapy of Melanoma
Johnson, D. B., & Sosman, J. A. (2013) · Current Treatment Options in Oncology · doi:10.1007/s11864-013-0226-8 · Cited by 65
New drug targets in metastatic melanoma
Homet, B., & Ribas, A. (2013) · The Journal of Pathology · doi:10.1002/path.4259 · Cited by 63
Cutaneous Melanoma in Childhood and Adolescence Shows Frequent Loss of INK4A and Gain of KIT
Daniotti, M., Ferrari, A., Frigerio, S., Casieri, P., Miselli, F., Zucca, E., Collini, P., Torre, G. D., Manoukian, S., Peissel, B., et al. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.422 · Cited by 63
Mutational and Functional Analysis Reveals ADAMTS18 Metalloproteinase as a Novel Driver in Melanoma
Wei, X., Prickett, T. D., Viloria, C. G., Molinolo, A., Lin, J. C., Cardenas-Navia, I., Cruz, P., Rosenberg, S. A., Davies, M. A., Gershenwald, J. E., et al. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0262 · Cited by 54
Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma
Buchbinder, E. I., Sosman, J. A., Lawrence, D. P., McDermott, D. F., Ramaiya, N. H., den Abbeele, A. D. V., Linette, G. P., Giobbie‐Hurder, A., & Hodi, F. S. (2015) · Cancer · doi:10.1002/cncr.29622 · Cited by 63
Kim, S. Y., & Yun, S. J. (2016) · Chonnam Medical Journal · doi:10.4068/cmj.2016.52.3.185 · Cited by 63
Patterns of Treatment Failure in Patients with Sinonasal Mucosal Melanoma
Amit, M., Tam, S. H., Abdelmeguid, A. S., Kupferman, M. E., Su, S. Y., Raza, S. M., DeMonte, F., & Hanna, E. Y. (2018) · Annals of Surgical Oncology · doi:10.1245/s10434-018-6465-y · Cited by 63
Systemic Therapies for Advanced Melanoma
Bomar, L., Senthilnathan, A., & Ahn, C. (2019) · Dermatologic Clinics · doi:10.1016/j.det.2019.05.001 · Cited by 63
The p53 Pathway and Outcome among Patients with T1G3 Bladder Tumors
López‐Knowles, E., Hernandez, S. F., Kogevinas, M., Lloreta, J., Amorós, À., Tardón, A., Carrato, A., Kishore, S. A., Serra, C., Malats, N., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0206 · Cited by 63
van der Rhee, J. I., Krijnen, P., Gruis, N. A., de Snoo, F. A., Vasen, H. F. A., Putter, H., Kukutsch, N. A., & Bergman, W. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.06.044 · Cited by 68
Fisher, K. E., Cohen, C., Siddiqui, M. T., Palma, J. F., Lipford, E. H., & Longshore, J. W. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.07.014 · Cited by 62
MTSS1 is a metastasis driver in a subset of human melanomas
Mertz, K. D., Pathria, G., Wagner, C., Saarikangas, J., Sboner, A., Romanov, J., Gschaider, M., Lenz, F., Neumann, F., Schreiner, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms4465 · Cited by 62
Therapy for metastatic melanoma: an overview and update
Boyle, G. M. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.25 · Cited by 62
Castañeda, C. A., Torres-Cabala, C. A., Castillo, M., Villegas, V., Casavilca-Zambrano, S. A., Cano, L., Sanchez, J., Dunstan, J. A., Calderón, G., Cruz, M. D. L., et al. (2017) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1685-3 · Cited by 62
GAB2 Amplifications Refine Molecular Classification of Melanoma
Chernoff, K. A., Bordone, L. A., Horst, B. A. J., Simon, K., Twadell, W. S., Lee, K., Cohen, J. A., Wang, S., Silvers, D. N., Brunner, G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0280 · Cited by 62
Lachiewicz, A. M., Berwick, M., Wiggins, C. L., & Thomas, N. E. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.18 · Cited by 62
Vemurafenib and ipilimumab: New agents for metastatic melanoma
Banaszynski, M., & Kolesar, J. (2013) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp120260 · Cited by 61
Farshidfar, F., Rhrissorrakrai, K., Levovitz, C., Peng, C., Knight, J., Bacchiocchi, A., Su, J., Yin, M., Sznol, M., Ariyan, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28566-4 · Cited by 62
Oncogenes in melanoma: An update
Kunz, M. (2014) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2013.12.002 · Cited by 61
Thomas, N. E., Kricker, A., From, L., BUSAM, K. J., Millikan, R. C., Ritchey, M. E., Armstrong, B. K., Lee‐Taylor, J., Marrett, L. D., Anton‐Culver, H., et al. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0686 · Cited by 62
Self-citationGrob, J., Amonkar, M. M., Martín‐Algarra, S., Демидов, Л. В., Goodman, V. L., Grotzinger, K. M., Haney, P., Kämpgen, E., Karaszewska, B., Mauch, C., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu154 · Cited by 61
Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm
Khattak, M. A., Fisher, R. A., Turajlic, S., & Larkin, J. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012466280 · Cited by 61
Molecular profiling, including TERT promoter mutations, of acral lentiginous melanomas
Vazquez, V. D. L., Vicente, A. L. S. A., Carloni, A. C., Berardinelli, G. N., Soares, P., Scapulatempo‐Neto, C., Martinho, O., & Reis, R. M. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000222 · Cited by 61
de la Fouchardière, A., Blokx, W. A. M., van Kempen, L. C. L. T., Luzar, B., Piperno-Neumann, S., Puig, S., Alós, L., Calonje, E. J., Massi, D., on behalf of the ESP Dermatopathology Working Group, et al. (2021) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-020-03005-1 · Cited by 61
Tormo, D., Ferrer, A., Gaffal, E., Wenzel, J., Basner‐Tschakarjan, E., Steitz, J., Heukamp, L. C., Gütgemann, I., Buettner, R., Malumbres, M., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060017 · Cited by 61
Targeting BRAF in melanoma: Biological and clinical challenges
Mandalà, M., & Voit, C. A. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2013.01.003 · Cited by 61
Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas
Egberts, F., Bergner, I., Krüger, S., Haag, J., Behrens, H.-M., Hauschild, A., & Röcken, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt411 · Cited by 61
Revisiting the photochemistry of solar UVA in human skin
Mitchell, D. L. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605833103 · Cited by 62
Sun, M. M., Kelly, S. P., Mylavarapu, A. L., Holland, G. N., Coleman, A. L., Yu, F., Stephen Hsu, M., Lum, F., & Gordon, L. K. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.11.001 · Cited by 60
Zhou, H. Y., Ekmekçioglu, S., Marks, J. W., Mohamedali, K. A., Asrani, K. V., Phillips, K. K., Brown, S. A. N., Cheng, E., Weiss, M. B., Hittelman, W. N., et al. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.402 · Cited by 60
Nucera, C., Goldfarb, M. R., Hodin, R. A., & Parangi, S. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.01.003 · Cited by 60
Analysis of the B-RAFV600E mutation in cutaneous melanoma patients with occupational sun exposure
CANDIDO, S., RAPISARDA, V., MARCONI, A., MALAPONTE, G., BEVELACQUA, V., GANGEMI, P., SCALISI, A., McCUBREY, J. A., MAESTRO, R., SPANDIDOS, D. A., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.2977 · Cited by 49
Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas
Rawson, R. V., Johansson, P. A., Hayward, N. K., Waddell, N., Patch, A., Lo, S., Pearson, J. V., Thompson, J. F., Mann, G. J., Scolyer, R. A., et al. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2016.143 · Cited by 60
Understanding spitzoid tumours: new insights from molecular pathology
Forno, P. D., Fletcher, A. A., Pringle, J. H., & Saldanha, G. S. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08207.x · Cited by 60
Autoimmunity and Immunotherapy for Cancer
Koon, H. B., & Atkins, M. B. (2006) · New England Journal of Medicine · doi:10.1056/nejme058307 · Cited by 60
Targeting Myeloid-Derived Suppressor Cells in Cancer
Anani, W. Q., & Shurin, M. R. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_8 · Cited by 59
Kyrgidis, Α., Tzellos, T., & Triaridis, S. (2010) · Journal of Carcinogenesis · doi:10.4103/1477-3163.62141 · Cited by 60
Acral lentiginous melanoma: Who benefits from sentinel lymph node biopsy?
Ito, T., Wada, M., Nagae, K., Nakano‐Nakamura, M., Nakahara, T., Hagihara, A., Furue, M., & Uchi, H. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.10.008 · Cited by 59
Lentigo Maligna: Melanoma In Situ on Chronically Sun-Damaged Skin
Reed, J. A., & Shea, C. R. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2011-0051-rair.1 · Cited by 59
Trametinib (GSK1120212) in the treatment of melanoma
Salama, A. K. S., & Kim, K. B. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.770475 · Cited by 60
Precision medicine driven by cancer systems biology
Filipp, F. V. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9662-4 · Cited by 62
Relevance of chromosomal band 11q13 in oral carcinogenesis: An update of current knowledge
Ramos‐García, P., Ruiz‐Ávila, I., Montoya, J. A. G., Ayén, Á., González‐Ruiz, L., Navarro‐Triviño, F. J., & González‐Moles, M. Á. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.04.016 · Cited by 59
Melanoma Biomarkers and Their Potential Application for In Vivo Diagnostic Imaging Modalities
Hessler, M., Jalilian, E., Xu, Q., Reddy, S., Horton, L. A., Elkin, K. B., Manwar, R., Tsoukas, M. M., Mehregan, D. R., & Avanaki, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249583 · Cited by 59
Li, S., Wu, X., Yan, X., Zhou, L., Chi, Z., Si, L., Cui, C., Tang, B., Mao, L., Lian, B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004036 · Cited by 60
Foltz, G., Yoon, J. G., Lee, H., Ryken, T. C., Sibenaller, Z. A., Ehrich, M., Hood, L., & Madan, A. (2009) · Oncogene · doi:10.1038/onc.2009.122 · Cited by 59
Nagore, E., Estrada, R. B., Requena, C., Serra-Guillén, C., Martorell, A., Hueso, L., Llombart, B., Sanmartín, O., & Guillén, C. (2009) · Actas Dermo-Sifiliográficas · doi:10.1016/s0001-7310(09)70536-8 · Cited by 58
Current Trends in Mucosal Melanomas: An Overview
Santeufemia, D. A., Palmieri, G., Miolo, G., Colombino, M., Doro, M. G., Frogheri, L., Paliogiannis, P., Capobianco, G., Madonia, M., Cossu, A., et al. (2023) · Cancers · doi:10.3390/cancers15051356 · Cited by 58
B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma
Shepherd, C., Puzanov, I. J., & Sosman, J. A. (2010) · Current Oncology Reports · doi:10.1007/s11912-010-0095-2 · Cited by 58
Molecular Pathways: Response and Resistance to BRAF and MEK Inhibitors in BRAFV600E Tumors
Thakur, M. D., & Stuart, D. D. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0103 · Cited by 58
MicroRNA Cancer Regulation: Advanced Concepts, Bioinformatics and Systems Biology Tools
Schmitz, U., Wolkenhauer, O., & Vera, J. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-5590-1 · Cited by 58
Current status and future direction in the management of malignant melanoma
Gladfelter, P., Darwish, N. H. E., & Mousa, S. A. (2017) · Melanoma Research · doi:10.1097/cmr.0000000000000379 · Cited by 58
BRAF kinase in melanoma development and progression
DeLuca, A. M., Srinivas, A., & Alani, R. M. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000604 · Cited by 60
Epigenetics and Dermatological Disease
Millington, G. W. M. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.12.1835 · Cited by 59
de Castro, D. G., Fearfield, L. A., Nathan, P., Tanière, P., Wallace, A. J., Brown, E. R., Harwood, C. A., Marsden, J. R., & Whittaker, S. J. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12248 · Cited by 58
Precision Cancer Medicine: The Future Is Now, Only Better
Tsimberidou, A. M., Eggermont, A. M. M., & Schilsky, R. L. (2014) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2014.34.61 · Cited by 57
Dermatological Adverse Events from BRAF Inhibitors: A Growing Problem
Belum, V. R., Fischer, A., Choi, J. N., & Lacouture, M. E. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0308-6 · Cited by 57
Erythropoietin receptor contributes to melanoma cell survival in vivo
Kumar, S. M., Zhang, G., Bastian, B. C., Arcasoy, M. O., Karande, P., Pushparajan, A., Ács, G., & Xu, X. (2011) · Oncogene · doi:10.1038/onc.2011.366 · Cited by 57
Self-citationTherapeutic Implications of KIT in Melanoma
Postow, M. A., & Carvajal, R. D. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31824b2404 · Cited by 57
Jalili, A., Mertz, K. D., Romanov, J., Wagner, C., Kalthoff, F., Stuetz, A., Pathria, G., Gschaider, M., Stingl, G., & Wagner, S. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069064 · Cited by 57
Kvaskoff, M., Whiteman, D. C., Zhao, Z., Montgomery, G. W., Martin, N. G., Hayward, N. K., & Duffy, D. L. (2011) · Twin Research and Human Genetics · doi:10.1375/twin.14.5.422 · Cited by 57
Girotti, M. R., Saturno, G., Lorigan, P. C., & Marais, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.027 · Cited by 59
Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study
van Not, O. J., de Meza, M. M., van den Eertwegh, A. J. M., Haanen, J. B. A. G., Blank, C. U., Aarts, M. J. B., van den Berkmortel, F. W. P. J., van Breeschoten, J., de Groot, J. B., Hospers, G. A. P., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.02.026 · Cited by 59
Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies
Utikal, J. S., Schadendorf, D., & Ugurel, S. (2007) · Archives of Dermatological Research · doi:10.1007/s00403-006-0726-5 · Cited by 57
Saha, N., & Muntean, A. G. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188498 · Cited by 56
Acral melanoma: new insights into the immune and genomic landscape
Carvalho, L. A. D. C., Aguiar, F. C., Smalley, K. S. M., & Possik, P. A. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100947 · Cited by 56
Regulation of NR4A nuclear receptor expression by oncogenic BRAF in melanoma cells
Smith, A. G., Lim, W., Pearen, M. A., Muscat, G. E. O., & Sturm, R. A. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00843.x · Cited by 56
Joseph, R. W., Peddareddigari, V. R., Liu, P., Miller, P. W., Overwijk, W. W., Bekele, N. B., Ross, M. I., Lee, J. E., Gershenwald, J. E., Lucci, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2769 · Cited by 55
Mutational status of naevus-associated melanomas
Shitara, D. I., Tell‐Martí, G., Bádenas, C., Enokihara, M. M. S. S., Alós, L., Larque, A. B., Michalany, N. S., Puig‐Butillé, J. A., Carrera, C., Malvehy, J., et al. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13829 · Cited by 57
Clinical Development of PD-1 in Advanced Melanoma
Munhoz, R. R., & Postow, M. A. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000299 · Cited by 56
Tichá, I., Hojny, J., Michálková, R., Kodet, O., Krkavcová, E., Hájková, N., Němejcová, K., Bártů, M., Jakša, R., Důra, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-53636-x · Cited by 56
Sarkar, S., & Gaddameedhi, S. (2020) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22370 · Cited by 57
Revealing the genomic heterogeneity of melanoma
Kabbarah, O., & Chin, L. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.11.008 · Cited by 56
Bradish, J. R., & Cheng, L. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.04.001 · Cited by 56
Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond
Menzies, A. M., & Long, G. V. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.027 · Cited by 55
Metadata
- Authors
- Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., Pinkel, D., & Bastian, B. C.
- Affiliations
- University of California, San Francisco (US)
- Kumamoto University Hospital (JP)
- Memorial Sloan Kettering Cancer Center (US)
- Dermatopathologie Friedrichshafen (DE)
- Seoul National University (KR)
- Tohoku University (JP)
- University of Würzburg (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-17
- Volume
- 353
- Issue
- 20
- Pages
- 2135-2147
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1989121777
- Cited by
- 2,747
- References
- 38
- Citations by year
- 2026: 54 · 2025: 69 · 2024: 87 · 2023: 91 · 2022: 85 · 2021: 125 · 2020: 165 · 2019: 133 · 2018: 130 · 2017: 164 · 2016: 157 · 2015: 170 · 2014: 197 · 2013: 218 · 2012: 202
- FWCI
- 33.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- National Cancer Institute (R01CA094963, R33 CA95300, R33CA095300)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- melanoma, UV exposure, acral melanoma, mucosal melanoma, BRAF mutation, NRAS mutation, copy number alterations, CDK4, CCND1, oncogenes, tumor genetic heterogeneity, skin cancer
- MeSH terms
- Adult, Aged, Aged, 80 and over, DNA, Neoplasm, Environmental Exposure, Female, Humans, Male, Melanoma, Middle Aged, Mutation, Nucleic Acid Hybridization, Genes, ras, Risk Factors, Skin Neoplasms, Ultraviolet Rays, Signal Transduction, Genome, Human, Phosphatidylinositol 3-Kinases, Cyclin D1, Mitogen-Activated Protein Kinases, Proto-Oncogene Proteins B-raf, PTEN Phosphohydrolase, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.